Essential fatty acids and mental illness

International Review of Psychiatry

Volumn 18, Issue 2, 2006, Pages 81-84

  Vaddadi, Krishna ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; GAMMA LINOLENIC ACID; LIPID; NEUROPROTECTIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; RESOLVIN; UNCLASSIFIED DRUG;

AGGRESSION; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BEHAVIOR DISORDER; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; FATTY ACID METABOLISM; GENE INTERACTION; HUMAN; LIPID ANALYSIS; LIPID BRAIN LEVEL; LONGITUDINAL STUDY; MEDICAL RESEARCH; MENTAL DISEASE; METABOLITE; MOOD DISORDER; NERVE CELL NETWORK; NEUROIMAGING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT PLANNING; VIOLENCE;

BRAIN; DIETARY SUPPLEMENTS; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; HUMANS; MEMBRANE LIPIDS; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; PHOSPHOLIPIDS;

EID: 33646898247     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260600581837     Document Type: Review

References (19)

1. Clandinin, M. T. J. J. (1997). Fatty acid metabolism in brain in relation to development, membrane structure and signalling. In D. I. Mostofsky & S. Yehuda (Eds.), Handbook of essential fatty acid biology, biochemistry and behavioural neurobiology. Totowa, New Jersey: Humana Press.
2. Das, U. N. (2002). Long-chain polyunsaturated fatty acids metabolism, physiology and clinical significance. In U. N. Das (Ed.), A perinatal strategy for preventing adult disease: The role of long-chain polyunsaturated fatty acids. Boston, Dordrecht, London: Kluwer Academic Publishers.
3. Frangou, S., Lewis, M., & McCrone, P. (2006). Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: Randomised double-blind placebo-controlled study. British Journal of Psychiatry, 188, 46-50.
4. Gesch, C. B., Hammond, S. M., Hampson, S. E., Eves, A., & Crowder, M. J. (2002). Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. British Journal of Psychiatry, 181, 22-28.
5. Haag, M. (2003). Essential fatty acids and the brain. Canadian Journal Psychiatry, 48, 195-203.
6. Halsted, C. H. (2000). Dietary supplements and the American Journal of Clinical Nutrition (1). American Journal of Clinical Nutrition, 71, 399-400.
7. Hargreaves, K. M., & Clandinin, M. T. (1988). Dietary control of diacylphosphatidylethanolamine species in brain. Biochimica et Biophysica Acta, 962, 98-104.
8. Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, E., Hayden, D., et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry, 62, 19-28.
9. Horrobin, D. F. (1999). The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopmental concept of schizophrenia. In M. Peet, I. Glen & D. F. Horrobin (Eds.), Phospholipid spectrum disorder in psychiatry (pp. 3-20). Lancashire, UK: Marius Press.
10. Horrobin, D. F., Glen, A. I., & Vaddadi, K. (1994). The membrane hypothesis of schizophrenia. Schizophrenia Research, 13, 195-207.
11. Joy, C. B., Mumby-Croft, R., & Joy, L. A. (2003). Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Systematic Review, CD001257.
12. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
13. McGahon, B., & Lynch, M. A. (1996). The synergism between metabotropic glutamate receptor activation and arachidonic acid on glutamate release is occluded by induction of long-term potentiation in the dentate gyrus. Neuroscience, 72, 847-855.
14. Puri, B. K., Leavitt, B. R., Hayden, M. R., Ross, C. A., Rosenblatt, A., Greenamyre, J. T., et al. (2005). Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology, 65, 286-292.
15. Sastry, P. S. (1985). Lipids of nervous tissue: Composition and metabolism. Progress in Lipid Research, 24, 69-176.
16. Tence, M., Murphy, N., Cordier, J., Premont, J., & Glowinski, J. (1995). Synergistic effects of acetylcholine and glutamate on the release of arachidonic acid from cultured striatal neurons. Journal of Neurochemistry, 64, 1605-1613.
17. Vaddadi, K. (2004). Eicosanoid precursors in the treatment of Huntington's disease. In P. Curtis-Prior (Ed.), The Eicosanoids (pp. 499-506). Chichester: Wiley.
18. Vaddadi, K. S., Courtney, P., Gilleard, C. J., Manku, M. S., & Horrobin, D. F. (1989). A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research, 27, 313-323.
19. van Dellen, A., & Hannan, A. J. (2004). Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics, 5, 9-17.